Iraq vs Mongolia: Average cost of multi drug-resistant tuberculosis treatment
Iraq
1,500 constant 2022 US$
in 2024
Mongolia
1,500 constant 2022 US$
in 2024
Iraq rank
34th
Mongolia rank
34th
Average cost of multi drug-resistant tuberculosis treatment over time
- Iraq
- Mongolia
How they compare
Iraq currently reports 1,500 constant 2022 US$ against 1,500 constant 2022 US$ in Mongolia, a difference of 0 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Iraq ahead.
Iraq ranks 34th and Mongolia ranks 34th of 92 countries.
Iraq has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Iraq | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 2,573 constant 2022 US$ | 1,427 constant 2022 US$ | Iraq |
| 2020s | 2,300 constant 2022 US$ | 1,455 constant 2022 US$ | 845.4 constant 2022 US$ | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Iraq or Mongolia?
- Iraq, at 1,500 constant 2022 US$ against 1,500 constant 2022 US$ in Mongolia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Iraq and Mongolia?
- 0 constant 2022 US$, with Iraq ahead.
- How many years of comparable data are there for Iraq and Mongolia?
- 8 years are reported by both, from 2017 to 2024.
- How do Iraq and Mongolia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Iraq ranks 34th and Mongolia ranks 34th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.